Introduction
============

Symptomatic mucosal candidiasis (MC) arises in subjects colonized with *Candida* who are predisposed by illness, debility, or a local reduction in host resistance to an overgrowth of their own indigenous flora ([@b46]; [@b70]). Colonization rates increase with severity of illness and duration of hospitalization ([@b33]).

Oral candidiasis has been described since Hippocrates, although Hippocrates used the term "aphthae" to describe this infection ([@b27]). Several clinical forms of oral candidiasis exist; thrush is the most commonly and widely recognized and is also called acute pseudomembranous candidiasis. Oropharyngeal candidiasis (OPC) may be the first manifestation of HIV infection and, approximately 80%--90% of patients with AIDS will develop oral candidiasis at some stage ([@b6]; [@b61]). Although not as frequent as OPC, esophageal candidiasis (EC) is reported in approximately 10% of patients with AIDS, and unlike OPC, is capable of producing incapacitating illness, wasting syndrome, and malnutrition ([@b20]; [@b43]). In addition, MC also occurs in individuals with underlying hematological malignancy, following solid organ transplantation, in those with congenital cell-mediated immune dysfunction, and following prolonged antimicrobial therapy ([@b32]; [@b33]; [@b59]).

Even in the era of highly active antiretroviral therapy (HAART), HIV-infected individuals continue to suffer from recurrent OPC/EC ([@b70]; [@b48]). With the advent of HAART fewer HIV-infected patients are developing OPC/EC. In contrast, rate of OPC and EC has not been altered in developing countries where HAART is not readily available. Antiretroviral therapy has not altered the relative frequency of AIDS-defining illnesses, and OPC/EC remains among the most common. Mucocutaneous candidiasis is usually seen in those patients with CD^4+^ counts less that 100/mm^3^ ([@b31]; [@b43]; [@b70]). In a population of individuals with median CD4^+^ counts of 100--110/mm^3^, the incidence of esophageal candidiasis is approximately 4 per 100 person-years of observation ([@b43]).

In the non-HIV infected individual, *C. albicans* accounts for approximately 70%--80% of oral isolates, while *C. glabrata* and *C. tropicalis* account for approximately 5%--8% each, and the other non-*albicans Candida* species are recovered only rarely ([@b70]). *C. albicans* is the species most often implicated in OPC/EC, consistently accounting for 90% or more of baseline isolates ([@b43]; [@b75]; [@b48]). There has been a significant increase in the frequency of non-*albicans Candida* species isolation in the HIV-infected individual ([@b3]; [@b67]). In the 1980s, non-*albicans Candida* species accounted for 3%--4 % of oral isolates recovered from HIV-infected patients, while in the 1990s, 17% of isolates recovered from HIV patients were non-*albicans Candida* species ([@b3]; [@b67]).

Therapy
=======

Prompt therapy with an antifungal agent is indicated ([@b70]; [@b48]). Unfortunately, almost all patients with AIDS and successfully treated MC will eventually develop a recurrence in the absence of immune reconstitution ([@b56]). Therefore, in addition to antifungal therapy, antiretroviral therapy should be instituted as soon as possible.

Although safe and efficacious therapies are available, among the presently available armamentarium, all agents have some limitations. Topical agents may be used for OPC, but are ineffective for EC. Numerous antifungal agents are available for the treatment of OPC ([Table 1](#tbl1){ref-type="table"}) and EC ([Table 2](#tbl2){ref-type="table"}). However, several factors must be considered when choosing antifungal agents for patients with HIV or AIDS. One important factor is efficacy. In HIV-positive patients, antifungals are less efficacious than in patients with cancer, and time to antifungal response is also more prolonged ([@b18]). In addition, the relapse rate is higher in patients with HIV than in other patient populations ([@b18]; [@b69]). Therefore, certain predisposed HIV-positive patients experience recurrent episodes of OPC and subsequently receive numerous courses of antifungals during their lifetime. As AIDS progresses, they frequently experience shorter intervals between episodes of OPC and esophageal candidiasis and thus more antifungal exposure, which may lead to antifungal resistance and severe morbidity ([@b68]).

###### 

Antifungals for the treatment of oropharyngeal candidiasis

  Antifungal agent   Form          Strength        Use
  ------------------ ------------- --------------- -------------------------------
  **Topical**                                      
  Nystatin           Pastille      200,000 units   Dissolve 1-2 pastilles qid
  Nystatin           Suspension    100,000 units   5 mL swish and swallow qid
  Clotrimazole       Oral troche   10 mg           Dissolve 1 troche 5 times/day
  Amphotericin B     Suspension    1 mg/mL         1 mL swish and swallow qid
  Amphotericin B     Lozenge       100 mg          qid
  Amphotericin B     Tablet        10 mg           qid
  **Systemic**                                     
  Ketoconazole       Tablet        200 mg          1-2 tablets qd-bid
  Fluconazole        Tablet        100 mg          1 tablet qd
  Fluconazole        Solution      10 mg/mL        10 ml qd
  Itraconazole       Capsule       100 mg          200 mg qd
  Itraconazole       Solution      10 mg/mL        10-20 ml qd-bid
  Posaconazole       Suspension    100 mg/2.5 mL   100 mg qd

Derived from data of [@b70]

**Notes**: qid, four times daily; tid, three times daily; bid, twice daily; qd, once daily

###### 

Antifungals for the treatment of esophageal candidiasis

  Antifungal Agent   Form       Strength   Use
  ------------------ ---------- ---------- ---------------------
  Ketoconazole       Tablet     200 mg     1--2 tablets qd-bid
  Fluconazole        Tablet     100 mg     1 tablet qd
  Fluconazole        Solution   10 mg/ml   10ml qd
  Itraconazole       Capsule    100 mg     200 mg qd
  Itraconazole       Solution   10 mg/ml   10--20 mL qd-bid
  Voriconazole       tablet     200 mg     1 tablet bid

Derived from data of [@b70]

**Notes:** bid, twice daily; qd, once daily

Another possibly more important factor to consider when managing recurrent fungal infections in HIV-positive patients is the long-term consequences of antifungal therapy on mycoflora. It is important to note that, as with many infections in this patient population, antifungal treatment merely reduces the signs and symptoms of infection, and thus produces a transient clinical response by lowering the quantity of organisms in the affected area. It is difficult to eradicate yeast from the body of a patient infected with HIV ([@b68]; [@b70]). Subsequently, this leads to numerous courses of antifungals, development of antifungal resistance, and frequently, antifungal cross-resistance (Maenza et al 1997). This is reflected by the clinical ineffectiveness of antifungals to which a patient has not previously been exposed. Thus we are becoming increasingly aware that choosing the appropriate agent, even in the early stages of disease, is extremely important because of the future repercussions of this selection in the advanced stages of disease.

Presently available therapy which includes topical agents such as nystatin, amphotericin B, and clotrimazole are all somewhat effective, but tolerance and compliance are frequently problematic ([@b36]; [@b54]; [@b69]). In addition, topical agents are ineffective in EC, thus mandating systemic antifungal therapy ([@b69]).

Nystatin is the time-honored treatment for oral thrush in otherwise healthy adults and infants. Its limitations include bitter taste, gastrointestinal (GI) side-effects, and a 4 times a day regimen, all of which eventually lead to reduced adherence and lower efficacy ([@b53]; [@b69]). More importantly, is its lack of efficacy in severely immunocompromised patients, such as those with HIV/AIDS ([@b54]; [@b53]). In a published study comparing the efficacy of nystatin and oral fluconazole in HIV-positive patients, the clinical cure rate of nystatin was 52%, compared with 87% for fluconazole ([@b53]). The mycological cure rate was also significantly lower for nystatin (6% vs 60%). In addition, the relapse rates 28 days after the end of therapy were 44% and 18%, respectively.

Amphotericin B oral suspension is also an alternative antifungal agent ([@b36]; [@b69]). In addition to the suspension, amphotericin B is also available as a lozenge and tablet. Like nystatin, it is not absorbed from the GI tract and must to be given 4 times daily; however, it does not have an unpleasant taste. Unfortunately, comparative studies evaluating amphotericin B oral solution and other antifungals are limited.

Azole antifungals have essentially replaced the topical polyene agents for the treatment of OPC in AIDS ([@b7]). Clotrimazole 10 mg troches administered 5 times/day were successful in treating mild-to-moderate OPC during the early stages of HIV disease and during the initial episodes of oral candidiasis in patients with neoplastic diseases (Schectman et al 1984). In a study comparing oral fluconazole and clotrimazole troches for oral candidiasis in persons with HIV or AIDS, efficacy was essentially the same, 98% and 94%, respectively ([@b52]). At the end of antifungal therapy, fluconazole was more effective than clotrimazole in eradicating detectable yeast from the oral flora (65% vs 48%, respectively). In addition, patients receiving fluconazole were also more likely to remain asymptomatic through the second week of follow-up (82%) when compared with those receiving clotrimazole (50%).

Although topical therapy is frequently effective and relatively inexpensive, recurrent episodes of OPC in more advanced disease often require systemic azoles such as ketoconazole, fluconazole, itraconazole, and now posaconazole. Ketoconazole was the first available oral systemic imidazole antifungal agent and is highly effective even in debilitated patients ([@b7]). Clinical cure rates in excess of 75% have been achieved with daily ketoconazole administered for 10--14 days (Hughes et al 1993). In several comparative trials in patients with AIDS, ketoconazole was not as efficacious as fluconazole (70%--80% vs 94%--100%), and the mycological cure rates were also lower ([@b19]; [@b8]). Use of ketoconazole is limited by fears of hepatotoxicity and drug-drug interactions, and concerns about the reliability of gastric absorption and subsequent blood and tissue levels ([@b7]; [@b69]). The drug's absorption is markedly reduced under hypochlorhydric states. Thus, systemic absorption is a concern in patients with AIDS-related hypochlorhydria, and in those receiving H~2~-receptor antagonists (cimetidine, ranitidine,), sucralfate, antacids, didanosine, and proton pump inhibitors (omeprazole, lansoprazole) ([@b50]). In addition, since ketoconazole is a potent inhibitor of the cytochrome (CYP) P450 3A4 enzyme system, numerous reports describe interactions with the non-sedating H~1~-receptor antagonists (terfenadine, astemizole) and cisapride resulting in significant prolongation of the QT interval and occasional deaths due to cardiac dysrhythmias ([@b28]; [@b42]). Thus, concomitant administration of ketoconazole with drugs metabolized via the same pathway (cyclosporine, digoxin, HIV-protease inhibitors, and several sedatives such as triazolam and midazolam) may produce increased levels of the second drug ([@b42]).

The older triazoles, fluconazole and itraconazole, have demonstrated excellent efficacy and safety profiles for many years, and have become the most frequently prescribed antifungals, especially for patients with HIV or AIDS ([@b24]; [@b41]; [@b45]). The clinical efficacy of fluconazole 50--100 mg/day was evaluated in several open-label and placebo-controlled trials and in double-blind comparative studies versus clotrimazole or ketoconazole in patients with either hematologic or solid organ malignancy or HIV infection ([@b24]; [@b34]; [@b41]). Although most studies utilized a 100 mg daily dose, clinical efficacy has been achieved with a dose of 50 mg/day ([@b24]). Clinical response was achieved in 80% of patients with severe underlying disease with the low dose of fluconazole. However, complete mycological cure is more difficult to attain. A striking feature of fluconazole is the rapidity of response, usually within 10 days with fluconazole 50 mg/day and within 5 days with 100--200 mg/day, even in the most severe forms of thrush associated with AIDS ([@b24]; [@b18]). In addition, overall clinical response rates indicate that failure is rare, and in most published studies, 80% or more of patients were clinically cured, with another 10%--15% experiencing considerable improvement ([@b69]).

Itraconazole has a broad spectrum of activity, and like other azoles, it inhibits the synthesis of fungal ergosterol. Since the capsule formulation has variable absorption, a cyclodextrin solution formulation has been developed and is generally the formulation utilized in OPC/EC ([@b4]). In a pharmacokinetic study, the solution demonstrated a 30% increase in itraconazole absorption. In addition, the solution has a much greater bioavailability in fasting patients compared with post-prandial administration ([@b29]; [@b66]). A prospective, randomized trial in HIV-positive and AIDS patients with OPC, compared itraconazole oral solution 200 mg/day and fluconazole 100/mg day for 14 days ([@b22]). Clinical response rates were 97% for itraconazole and 87% for fluconazole, with few adverse events in both groups. However, approximately 50% of the patients in both groups experienced relapses at the 1-month follow-up evaluation.

Overall, itraconazole and fluconazole, have demonstrated an improved safety profile compared with other antimycotic agents; nevertheless, they must be used with caution. Itraconazole has similar drug interactions as ketoconazole due to the inhibition of the same CYP3A4 enzyme system ([@b29]; [@b42]). Fluconazole is associated with fewer drug-drug interactions because it has less affinity for the enzyme ([@b35]; [@b42]). The pharmacological interactions with fluconazole include phenytoin, rifampin, rifabutin, cyclosporin A, and possibly some of the protease inhibitors ([@b35]; [@b63]; [@b42]). In certain situations, fluconazole may offer an advantage over ketoconazole or itraconazole because of the lower potential to produce drug-drug interactions.

The optimal antifungal agent for OPC is not known, but evaluation of the most recent literature seems to suggest that until now fluconazole and itraconazole appear to be the most appropriate agents in patients with HIV infection or AIDS.

Since topical agents are ineffective in the management of EC, relatively few oral drugs for systemic infection are available ([@b70]; [@b48]). The current guidelines of the Infectious Diseases Society of America recommend the use of systemic antifungal therapy ([@b48]). Currently available therapy includes oral and parenteral azoles (ketoconazole, fluconazole, itraconazole, and voriconazole) or parenteral polyenes (amphotericin B). More recently, the echinocandins (caspofungin \[Cancidas^®^, Merck & Co., Inc.\]; micafungin \[Mycamine^®^, Astellas Pharma US, Inc.\]; and anidulafungin \[Eraxis^®^, Pfizer Inc.\]) have all been approved for the treatment of EC.

Amphotericin B, the agent of choice for many years is no longer acceptable as first line therapy in most situations due to unacceptable nephrotoxicity and infusion-related reactions.

Voriconazole (Vfend^®^, Pfizer Inc.) is a newer triazole that has been shown to be 10- to 500-fold more potent in vitro than fluconazole against a wide spectrum of fungi, including fluconazole resistant *Candida* species ([@b8]; Pfizer 2005). Voriconazole 200 mg bid was approved for the treatment of EC in November 2004. In a randomized, double-dummy, double-blind, multicenter trial voriconazole 200 mg bid was compared with fluconazole 200 mg daily in esophageal candidiasis ([@b2]). Overall success rates were comparable 98.2% for voriconazole compared with 95% for fluconazole. The overall safety and tolerability of both agents was similar.

The echinocandins are a relatively new class of antifungal, with a completely different mechanisms of action ([@b23]). All three are broad-spectrum and demonstrate excellent in vitro activity against most *Candida* species, including those species that are fluconazole-resistant ([@b23]). All three echinocandins have been approved for the treatment of EC. Thus far, 5 different clinical trials evaluating echinocandins in EC have been completed. The clinical studies compare the echinocandins to either fluconazole or amphotericin B ([@b23]). Overall, all three echinocandins demonstrated non-inferiority to the comparator in each of the five clinical trials. In addition, the overall safety profile was excellent for the three echinocandins. The two major concerns with the echinocandins in the management of EC are that there are no oral formulations thus mandating the use of parenteral therapy for a minimum of 2--3 weeks, or a switch to an oral azole, and the relapse rates of EC using the echinocandins appears to be slightly higher than the comparators (fluconazole or amphotericin B). Nevertheless, clinical relapse is not uncommon, particularly in patients with persistence of underlying immunodeficiency (eg, AIDS, chronic mucocutaneous candidiasis). Relapse appears to depend on duration of therapy and degree of immunosuppression, and may occur sooner following clotrimazole and ketoconazole therapy than after itraconazole or fluconazole therapy ([@b19]; [@b69]).

The clinical impact of antifungal resistance in patient with AIDS has been demonstrated in patients who fail standard antifungal therapy for OPC ([@b68]). After the onset of fluconazole-resistant thrush, patients had a median survival of 184 days. Moreover, after the onset of clinical resistance to amphotericin B, the patients had an astonishing 83-day median survival rate. Although mucosal candidiasis does not produce death directly, clinical failure is probably a co-morbidity factor in the rapid demise of these patients. Clinical failure is also a marker of severe immunosuppression and a nonfunctional immune system.

It is still not clear whether the total dose of antifungals, the duration of therapy, type of antifungal, or pattern of drug administration (continuous or episodic) are the most important determinants in the development of antifungal-refractory fungal disease ([@b40]). More than likely it is multifactorial, involving a combination of advanced immunosuppression, high fungal burdens, and prolonged exposure to antifungals ([@b39]).

In addition to microbial resistance, reasons for recurrence of OPC or refractory disease include patient non-compliance, the degree of immunosuppression, drug interactions, and altered drug bioavailability ([@b40]). These limitations underscore the need for new agents that may provide advantages such as safer delivery, fewer drug-drug interactions, and an improved antifungal spectrum.

Posanconazole (Noxafil^®^, Schering-Plough) is a potent, oral extended-spectrum triazole antifungal recently approved by the FDA ([@b26]) ([Figure 1](#fig1){ref-type="fig"}). It is approved for the treatment of OPC, including OPC refractory to itraconazole and/or fluconazole and for the prophylaxis of infections due to *Candida* and *Aspergillus* spp. in patients who are at high risk for such infections, such as those undergoing hematopoietic stem cell transplant (HSCT) with graft-versus host disease or with prolonged neutropenia due to a hematologic malignancy or its treatment ([@b58]).

Posaconazole, like other azole antifungals, inhibits lanosterol 14-alpha demethylase (CYP51), an enzyme that catalyzes the final step in the synthesis of ergosterol, an important component of the fungal cell membrane ([@b44]). Mutations near the heme cofactor of CYP51 appear to reduce the binding affinity of compact azoles such as fluconazole and voriconazole and may lead to azole resistance in *C. albicans* ([@b38]). However, results of a study using 3-dimensional binding models suggest that the long side chain of posaconazole may result in tighter binding affinity and appears to stabilize binding. It appears that mutations in the heme site have far less impact on the susceptibility of the organisms to posaconazole, compared with fluconazole or voriconazole. Thus a greater number of mutations may be required to generate resistance to posaconazole than to fluconazole or voriconazole ([@b5]; [@b38]; [@b76]). In addition, posaconazole is a substrate of the major facilitator pumps encoded by *CDR1* and *CDR2* in *C. albicans*, but is not a substrate of the major facilitator pumps encoded by *MDR1* and *FLU1* that efflux fluconazole ([@b25]). Posaconazole may be less susceptible than some azoles to the development of secondary azole resistance. In essence, although fluconazole and even voriconazole may demonstrate resistance to fluconazole, the majority of the time posaconazole will retain its in vitro susceptibility ([@b5]; [@b38]; [@b76]).

![Structure of posaconazole.](tcrm0304-533-01){#fig1}

In vitro activity
=================

Posaconazole has demonstrated in vitro activity against *Aspergillus*, *Fusarium* and the Zygomycetes. Its activity in vitro against *Candida* spp. is similar to that of voriconazole, and includes itraconazole- and fluconazole-resistant strains of *Candida*, such as *C. glabrata*, and *C. krusei* ([@b57]). In vitro assays demonstrate posaconazole MIC~90~ values for *C. albicans*, *C. parapsilosis*,*C. tropicalis*, *C.lusitaniae*, and *C. dubliniensis* of 0.06--0.5 μg/mL, while MIC~90~ values for *C. krusei* and *C. glabrata* range from 0.5 to 4 μg/mL ([@b47]; [@b26]) ([Table 3](#tbl3){ref-type="table"}).

###### 

In vitro susceptibilities of *Candida* spp. to posaconazole, fluconazole, and itraconazole

                                    Posaconazole                           Fluconazole                           Itraconazole   
  ------------------- ------------- -------------- --------- ------------- ------------- --------- ------------- -------------- ---------
  **Organism**        **Range**     **50%**        **90%**   **Range**     **50%**       **90%**   **Range**     **50%**        **90%**
  *C. albicans*       ≤0.004-16     0.003          0.06      0.12-- \>64   0.25          0.5       \<0.004--16   0.003          0.12
  *C. glabrata*       0.3-- \>4     0.5            2.0       0.25-- \>64   16            \>64      0.03-- \>4    1              8
  *C. parapsilosis*   0.03--0.12    0.12           0.12      0.12--2.0     0.5           1         0.015--0.25   0.12           0.12
  *C. tropicalis*     0.03-- \> 4   0.12           0.12      0.12-- \>64   0.5           2.0       0.015-- \>4   0.12           0.5
  *C. krusei*         0.03--0.5     0.5            0.5       8-- \>64      32            \>64      0.12--2       0.5            0.5
  *C. dublinieusis*   0.015--0.25   0.30           0.06      0.12-- \>64   0.12          0.5       0.015--0.5    0.06           0.25
  *C. lusitaniae*     0.015--0.12   0.12           0.12      0.12--8       1             2         0.03--0.5     0.12           0.5

Pharmacokinetics ([Table 4](#tbl4){ref-type="table"})
=====================================================

Absorption and distribution
---------------------------

Posaconazole is orally absorbed, with the greatest exposure achieved when it is administered as an oral suspension ([@b14]). Following administration of rising single or multiple doses (tablet formulation) to healthy subjects, posaconazole exhibits dose-proportional pharmacokinetics up to 800 mg/day ([@b11]). No increase in area under the plasma concentration-time curve (AUC) values is observed when the posaconazole dose is increased from 800 to 1200 mg/day. Following administration of the tablet or suspension formulations, posaconazole has an extensive volume of distribution (343--1341 L) and a long half-life (t~½~ approximately 25--35 h) ([@b14], [@b11], [@b12]), with peak plasma concentrations attained at approximately 5--6 hours after dose. Steady state concentrations are attained at 7--10 days.

###### 

Pharmacokinetics of posaconazole

  Variable                     Value
  ---------------------------- ----------------------------------
  Volume of distribution (L)   1774
  Protein binding (%)          \>98
  Elimination                  Via feces (77%)
                               Via urine (1%)
  Half-life (hours)            35 (20--66)
  Metabolism                   Biotranformation via UDG pathway

Derived from data of Herbrecht (2004).

**Abbreviations:** UDG, uridine diphosphate -- glucoronosyltransferase

Posaconazole exposure is enhanced by co-administration with food. In a randomized, single-dose, open-label study conducted in 20 healthy male volunteers, administration of posaconazole with non-fat meal and a high-fat meal increased the AUC~(0--72)~ 2.6- and 4-fold, respectively (p \< 0.001 vs administration under fasting conditions) ([@b17]). Similarly, administration of posaconazole with a nutritional supplement (Boost^®^ Plus; MeadJohnson^®^ Nutritionals, Evansville, Indiana, USA) increased maximum plasma concentrations (C~max~) and AUC~(0--72)~ 3.4- and 2.6-fold, respectively ([@b12]).

When food intake is limited because of mucositis or other gastrointestinal dysfunction, dividing the daily dose enhances posaconazole's bioavailability. In a study of healthy male volunteers (n = 18) given posaconazole 800 mg/day under fasted conditions, 200 mg qid and 400 mg bid dosing was associated with increases in C~max~ and time to maximum plasma concentrations (t~max~) compared with once-daily dosing (Ezzet et al 2006). Administration in split doses also improved estimated AUC, which doubled and tripled with twice-daily and qid dosing, respectively.

Metabolism/elimination
----------------------

Posaconazole is primarily metabolized in the liver, where it undergoes glucuronidation and transformation into other biologically inactive metabolites ([@b37]). Approximately, 14% of an administered dose is excreted as multiple glucuronidated derivatives in the urine; an additional 77% is eliminated as parent compound in the feces. Minor amounts are excreted as parent compound in the urine.

Unlike itraconazole and voriconazole, posaconazole is not primarily metabolized by fungal cytochrome P450 enzymes (CYP450) ([@b74]). Thus, co-administering drugs that interact with the CYP450 enzyme system may alter itraconazole and voriconazole plasma concentrations, but is unlikely to alter posaconazole plasma concentrations. An evaluation of the effects of posaconazole on the various CYP450 enzymes demonstrated an inhibitory effect on CYP3A4 activity, but no influence on the activity of the other isoenzymes (CYP1A2, CYP2C8/9, CYP2D6 or CYP2E1) ([@b74]). In contrast to other azoles that are known to inhibit a variety of CYP450 drug-metabolizing isoenzymes ([@b1]; [@b69]; [@b73]), posaconazole is unique in that its effects on CYP450 enzyme activity are relatively limited. Therefore, posaconazole has the potential for fewer drug interactions compared with other azoles.

Special populations
-------------------

Posaconazole pharmacokinetics are not significantly influenced by age, gender, or ethnicity ([@b10], d, e). Therefore, no dose adjustments are necessary to accommodate for differences in these patient factors. Furthermore, renal or hepatic impairment has no significant influence on the pharmacokinetics of posaconazole ([@b9]; [@b16]).

Clinical trials
===============

A multicenter, randomized, evaluator-blinded study compared the efficacy of posaconazole 100 mg daily to fluconazole 100 mg daily for the treatment of OPC in patients infected with HIV ([@b71]). The primary end point was defined as clinical success on day 14. Three-hundred fifty subjects were enrolled into the study, 178 received posaconazole and 172 received fluconazole. Clinical success occurred in 91.7% of patients treated with posaconazole and 92.5% of those treated with fluconazole, with a mycological success of 68% in both arms. On follow up day 42, mycological success remained greater in the posaconazole group (40.6% vs 26.4%; p = 0.038) and fewer patients in this group had experienced clinical relapses (31.5% vs 38.2%). Although it did not meet statistical superiority, it appears that posaconazole was somewhat more effective than fluconazole in preventing a clinical relapse 6 weeks after the conclusion of antifungal therapy. In general, adverse events were uncommon and were similar in both groups.

In a separate clinical trial, oral posaconazole was evaluated in the management of OPC/EC that was clinically refractory to either fluconazole or itraconazole ([@b62]). In this study, oral posaconazole was used in subjects with confirmed OPC or EC who failed to improve on conventional courses of either fluconazole at 100 mg daily or itraconazole 200 mg daily for a minimum of 10 days. Study subjects received either posaconazole 400 mg bid for 3 days, followed by 400 mg daily for 25 days or posaconazole 400 mg bid for 28 days. The primary end point was either cure or improvement after 28 days of therapy. In the modified intent-to-treat population (MITT), 75% (132/176) of treated subjects achieved a clinical response to posaconazole. Clinical response was similar in both dosing regimens (75.3% vs 74.7%). In addition, in the 43 patients who also had endoscopically proven EC, the clinical response rate was documented to be 74.4%.

Although in this study, patients were on study drug for a prolonged period of time (28 days), the overall incidence of adverse events associated with the study drug was low. The most commonly observed adverse events included diarrhea (11%), neutropenia (7%), flatulence (6%), and nausea (6%). Only 8 patients discontinued posaconazole because of treatment-related adverse events. The study concluded that posaconazole is a safe and effective treatment option for patients with HIV infection suffering from azole-refractory OPC/EC.

To further evaluate the safety and efficacy of long-term posaconazole in patients with azole-refractory OPC/EC, a non-comparative open-label study was performed ([@b72]). Subjects who responded to the above mentioned trial, were eligible for a long term suppressive study. During the study period all patients received posaconazole 400 mg twice daily for up to 3 months. If patients were stable and clinically cured at three months, they were continued on therapy for up to 12 months. After the 12-month treatment course, 85.6% of subjects continued to remain symptom free. Posaconazole was well tolerated, with minimal adverse events. Overall, this study established that posaconazole at 400 mg twice daily demonstrated long-term safety, tolerability, and efficacy, thus offering a safe and long-term suppressive treatment option for HIV-infected subjects suffering from azole-refractory mucosal candidiasis.

Safety
======

Posaconazole has been relatively well tolerated in all clinical trials thus far. The most common adverse effects have been nausea and headache. Rash, dry skin, dizziness, paresthesias, and flushing have been described.

The most common adverse events reported in posaconazole clinical studies are of gastrointestinal in origin (eg, nausea, vomiting, dyspepsia, taste disturbance, diarrhea, and abdominal pain), as would be expected with a triazole ([@b26]; [@b62]; [@b71]). Elevated liver enzyme levels are rarely reported, and most are mild to moderate in severity and are similar to those observed in placebo-treated subjects ([@b11]; [@b62]). In healthy volunteers who received single or multiple posaconazole doses up to 1200 mg/day, no QT interval prolongation or other clinically relevant changes in electrocardiogram results have been observed ([@b11]). Long-term administration of posaconazole does not appear to be associated with a different adverse event profile than short-term administration ([@b55]; [@b62]; [@b65]; [@b72]). Discontinuations because of adverse events were described in only two study reports. One report indicated that 22 of 98 patients with febrile neutropenia or refractory invasive fungal infections discontinued posaconazole therapy prematurely because of adverse events; however, most of these events were not related to posaconazole therapy (Ullmann et al 2006). The other report described one premature discontinuation because of nausea, vomiting and diarrhea, which were attributed to infection with *Cryptosporidium* and acid-fast bacteria, not posaconazole therapy ([@b51]).

Based on this limited number of subjects with severe underlying diseases, it appears that the adverse event profile is similar to that of fluconazole, with the most common events gastrointestinal in origin and with low incidence of hepatic or renal toxicity or rash. Additionally, visual adverse events such as those seen with voriconazole have not been reported ([@b49]).

Drug interactions
=================

Posaconazole is only an inhibitor of CYP3A4, thus it may potentate the effect and toxicity of drugs metabolized by this enzyme, including phenytoin, midazolam, rifabutin, cyclosporine, and tacrolimus; if given with posaconazole, cyclosporine doses should be reduced by one-quarter and tacrolimus doses by two-thirds, and serum levels of each should be monitored. Concurrent use of posaconazole with ergot alkaloids, pimozide, cisapride, halofantrine, astemizole, and quinidine is contraindicated ([@b74]).

Dosage
======

The recommended dose of posaconazole for OPC is a loading dose of 100 mg (2.5 mL) by mouth twice a day for the first day, followed by 100 mg daily for 13 days. For refractory OPC, the recommended dosage is 400 mg (10 mL) twice daily based on the severity of illness. Most patients receive 21--28 days of antifungal therapy. Posaconazole should be administered along with a full meal or with a liquid nutritional supplement. According to the manufacturer, if a full meal or supplement cannot be taken, alternative antifungal agents should be considered.

Conclusions
===========

Numerous advances in antifungal therapy have been made in the last decade. The impressive results and minimal toxicity of azole compounds continue to make them attractive in the management of fungal infections in patients with AIDS. However, difficulties in managing these infections should remind us that we cannot rely on antifungals alone. We must continue to find ways to improve the body's dysfunctional immune system. In addition, we must continue to develop more effective antifungal agents with different mechanisms of action and different modes of administration.

Clinical trials demonstrate that posaconazole is as effective as fluconazole in producing a successful outcome in HIV-infected patients with OPC. In addition, posaconazole was more effective than fluconazole in sustaining clinical success after completing antifungal therapy. Furthermore, in a separate long-term clinical trial, posaconazole also demonstrated to be effective in HIV-infected patients suffering from azole-refractory OPC/EC. In the several clinical trials conducted thus far, posaconazole has been established as an extremely safe and very tolerable antifungal agent, similar to either fluconazole or itraconazole.

Overall, posaconazole's extended spectrum of activity, tolerability, long-term efficacy, safety profile and ease of use verify that it is an important addition to the antifungal armamentarium used to manage OPC and EC in any population. Posaconazole has also proven to be especially effective in the difficult to treat HIV-infected population suffering from azole refractory MC.
